FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008169970> ?p ?o ?g. }

• W3008169970 endingPage "TPS607" @default.
• W3008169970 startingPage "TPS607" @default.
• W3008169970 abstract "TPS607 Background: Few patients with metastatic urothelial carcinoma (UC) achieve a durable response despite early stabilization with chemotherapy or immunotherapy. Mutations in the COMPASS-related proteins KMT2D, KMT2C, and KDM6A are found in 66% of patients with UC, suggesting disruption of histone regulation may be an acquired mechanism of tumor viability. Using a carcinogen-derived mouse model of UC in which 80% of animals have alterations in Kmt2d, Kmt2d or both, we found regression of tumors when treated an enzymatic inhibitor of EZH2 (Tazemetostat). In vivo administration of Tazemetostat enhanced the immune response with more necrosis when combined with an anti-PD1 antibody. Therefore, we hypothesized that treatment of UC with an Tazemetostat may further improve the activity of immunotherapy as only 21% of cisplatin refractory (KN45) and 24% of cisplatin ineligible (KN52) patients achieve an objective response. We hypothesized that restoration of the epigenetic imbalance, combined with immunotherapy may improve survival in patients with metastatic UC. Methods: ETCTN10183 (NCT03854474) is a Phase I/II trial evaluating the efficacy of Tazemetostat at 800 mg BID + Pembrolizumab 200 mg IV every 3 weeks in patients with either cisplatin-refractory (Cohort A) or cisplatin-ineligible (Cohort B) metastatic UC. The safety lead-in portion of the trial will follow a “3+3” design with one dose de-escalation level (800mg or 600mg BID Tazemetostat) and will enroll 6-12 patients to establish the recommended phase II dose (RP2D) of Tazemetostat. All DLTs will be reviewed and if tolerated, two dose expansion cohorts will be initiated and will include 24 patients with 12 in each cohort (cisplatin refractory and ineligible). The primary objectives are to identify the RP2D of Tazemetostat in combination with Pembrolizumab, and secondary objectives are to determine the objective disease response in patients with either cisplatin-refractory or unresponsive UC per RECIST criteria, safety, tolerability and progression-free survival. Translational objectives include evaluation of tumor mutations in COMPASS genes, total mutation burden, T cell infiltration, TCR clonality, tumor subtyping and PD-L1 expression. Clinical trial information: NCT03854474." @default.
• W3008169970 created "2020-03-06" @default.
• W3008169970 creator A5010551367 @default.
• W3008169970 creator A5029331756 @default.
• W3008169970 creator A5033876610 @default.
• W3008169970 creator A5041126882 @default.
• W3008169970 creator A5070812529 @default.
• W3008169970 creator A5074874280 @default.
• W3008169970 creator A5082413734 @default.
• W3008169970 date "2020-02-20" @default.
• W3008169970 modified "2023-09-23" @default.
• W3008169970 title "A pilot study of tazemetostat and MK-3475 (pembrolizumab) in advanced urothelial carcinoma (ETCTN 10183)." @default.
• W3008169970 doi "https://doi.org/10.1200/jco.2020.38.6_suppl.tps607" @default.
• W3008169970 hasPublicationYear "2020" @default.
• W3008169970 type Work @default.
• W3008169970 sameAs 3008169970 @default.
• W3008169970 citedByCount "5" @default.
• W3008169970 countsByYear W30081699702020 @default.
• W3008169970 countsByYear W30081699702022 @default.
• W3008169970 countsByYear W30081699702023 @default.
• W3008169970 crossrefType "journal-article" @default.
• W3008169970 hasAuthorship W3008169970A5010551367 @default.
• W3008169970 hasAuthorship W3008169970A5029331756 @default.
• W3008169970 hasAuthorship W3008169970A5033876610 @default.
• W3008169970 hasAuthorship W3008169970A5041126882 @default.
• W3008169970 hasAuthorship W3008169970A5070812529 @default.
• W3008169970 hasAuthorship W3008169970A5074874280 @default.
• W3008169970 hasAuthorship W3008169970A5082413734 @default.
• W3008169970 hasConcept C121608353 @default.
• W3008169970 hasConcept C126322002 @default.
• W3008169970 hasConcept C143998085 @default.
• W3008169970 hasConcept C2776694085 @default.
• W3008169970 hasConcept C2777701055 @default.
• W3008169970 hasConcept C2778239845 @default.
• W3008169970 hasConcept C2780057760 @default.
• W3008169970 hasConcept C71924100 @default.
• W3008169970 hasConcept C98274493 @default.
• W3008169970 hasConceptScore W3008169970C121608353 @default.
• W3008169970 hasConceptScore W3008169970C126322002 @default.
• W3008169970 hasConceptScore W3008169970C143998085 @default.
• W3008169970 hasConceptScore W3008169970C2776694085 @default.
• W3008169970 hasConceptScore W3008169970C2777701055 @default.
• W3008169970 hasConceptScore W3008169970C2778239845 @default.
• W3008169970 hasConceptScore W3008169970C2780057760 @default.
• W3008169970 hasConceptScore W3008169970C71924100 @default.
• W3008169970 hasConceptScore W3008169970C98274493 @default.
• W3008169970 hasFunder F4320332161 @default.
• W3008169970 hasIssue "6_suppl" @default.
• W3008169970 hasLocation W30081699701 @default.
• W3008169970 hasOpenAccess W3008169970 @default.
• W3008169970 hasPrimaryLocation W30081699701 @default.
• W3008169970 hasRelatedWork W2342781363 @default.
• W3008169970 hasRelatedWork W2610751918 @default.
• W3008169970 hasRelatedWork W2777867648 @default.
• W3008169970 hasRelatedWork W2786497694 @default.
• W3008169970 hasRelatedWork W2969782175 @default.
• W3008169970 hasRelatedWork W3153432702 @default.
• W3008169970 hasRelatedWork W3161613553 @default.
• W3008169970 hasRelatedWork W3175277114 @default.
• W3008169970 hasRelatedWork W3215044659 @default.
• W3008169970 hasRelatedWork W4296773547 @default.
• W3008169970 hasVolume "38" @default.
• W3008169970 isParatext "false" @default.
• W3008169970 isRetracted "false" @default.
• W3008169970 magId "3008169970" @default.
• W3008169970 workType "article" @default.